US2011135648A1PendingUtilityA1

Anti-neublastin antibodies and uses thereof

57
Assignee: BIOGEN IDEC INCPriority: Aug 8, 2007Filed: Aug 5, 2008Published: Jun 9, 2011
Est. expiryAug 8, 2027(~1 yrs left)· nominal 20-yr term from priority
Inventors:Anthony RossomandoPing Jin
C07K 2317/76C07K 2317/24C07K 16/22C07K 2317/21G01N 33/6827C07K 2317/55A61P 35/00C07K 2317/54C07K 16/18C07K 2317/622
57
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Antibodies and antigen binding fragments that bind to neublastin polypeptides are disclosed. Also disclosed are methods of using the antibodies and antigen binding fragments in assays for detecting the presence or amount of endogenous and/or exogenous neublastin in a sample and in methods of antagonizing neublastin bioactivity.

Claims

exact text as granted — not AI-modified
1 . An isolated antibody or antigen-binding fragment thereof that selectively binds to the polypeptide of SEQ ID NO:1 on the same epitope as the antibody produced by the hybridoma deposited in the ATCC under Accession No. PTA-7624 or PTA-7625. 
     
     
         2 . An isolated antibody or antigen-binding fragment thereof that selectively binds to the polypeptide of SEQ ID NO:1 and crossblocks binding of the antibody produced by the hybridoma deposited in the ATCC under Accession No. PTA-7624 or PTA-7625. 
     
     
         3 . The antibody or antigen-binding fragment thereof of  claim 1 , wherein the antibody or antigen-binding fragment thereof is a monoclonal antibody, a polyclonal antibody, a humanized antibody, a fully human antibody, a single chain antibody, a chimeric antibody, an Fab fragment, an F(ab′)2 fragment, an Fab′ fragment, an Fsc fragment, or an Fv fragment. 
     
     
         4 . An antibody produced by the hybridoma deposited in the ATCC under Accession No. PTA-7624 or PTA-7625. 
     
     
         5 . A conjugate comprising the antibody or antigen-binding fragment thereof of  claim 1  linked to a detectable label. 
     
     
         6 . The conjugate of  claim 5 , wherein the detectable label is horseradish peroxidase or alkaline phosphatase. 
     
     
         7 . The conjugate of  claim 5 , wherein the detectable label is a fluorescent or radio-labeled marker. 
     
     
         8 . A conjugate comprising the antibody or antigen-binding fragment thereof of  claim 1  linked to a solid-phase matrix. 
     
     
         9 . The conjugate of  claim 8 , wherein the solid-phase matrix is a multi-well assay plate, sepharose, agarose, or a magnetic bead. 
     
     
         10 . A pharmaceutical composition comprising the antibody or antigen-binding fragment thereof of  claim 1  and a pharmaceutically acceptable carrier. 
     
     
         11 . An isolated cell that produces the antibody or antigen-binding fragment thereof of  claim 1 . 
     
     
         12 . The hybridoma deposited in the ATCC under Accession No. PTA-7624 or PTA 7625. 
     
     
         13 . A method of determining the presence or amount of a neublastin polypeptide in a sample, the method comprising:
 contacting a sample with the antibody or antigen-binding fragment thereof of  claim 1  for a time sufficient for the antibody or antigen-binding fragment thereof to bind to a neublastin polypeptide, if present in the sample; and   detecting the presence or amount of the antibody or antigen-binding fragment thereof bound to the neublastin polypeptide to thereby determine the presence or amount of the neublastin polypeptide in the sample.   
     
     
         14 . The method of  claim 13 , wherein the method comprises:
 prior to the detecting step, contacting the sample with a second antibody or antigen-binding fragment thereof that selectively binds to the polypeptide of SEQ ID NO:1 for a time sufficient for the second antibody or antigen-binding fragment thereof to bind to the neublastin polypeptide bound to the antibody or antigen-binding fragment thereof of any of  claims 1  to  4 ; and   detecting the presence or amount of the second antibody or antigen-binding fragment thereof bound to the neublastin polypeptide.   
     
     
         15 . A method of determining the presence or amount of a neublastin polypeptide in a sample, the method comprising:
 contacting a sample with a first antibody or antigen-binding fragment thereof that selectively binds to the polypeptide of SEQ ID NO:1 on the same epitope as the antibody produced by the hybridoma deposited in the ATCC under Accession No. PTA-7625 for a time sufficient for the first antibody or antigen-binding fragment thereof to bind to a neublastin polypeptide, if present in the sample;   contacting the sample with a second antibody or antigen-binding fragment thereof that selectively binds to the polypeptide of SEQ ID NO:1 on the same epitope as the antibody produced by the hybridoma deposited in the ATCC under Accession No. PTA 7624 for a time sufficient for the second antibody or antigen-binding fragment thereof to bind the neublastin polypeptide, if bound to the first antibody or antigen-binding fragment thereof; and   detecting the presence or amount of the second antibody or antigen-binding fragment thereof bound to the neublastin polypeptide, to thereby determine the presence or amount of the neublastin polypeptide in the sample.   
     
     
         16 . The method of  claim 15 , wherein the first antibody is produced by the hybridoma deposited in the ATCC under Accession No. PTA-7625. 
     
     
         17 . The method of  claim 15 , wherein the second antibody is produced by the hybridoma deposited in the ATCC under Accession No. PTA-7624. 
     
     
         18 . A method of determining the presence or amount of a neublastin polypeptide in a sample, the method comprising:
 contacting a sample with a first antibody or antigen-binding fragment thereof that selectively binds to the polypeptide of SEQ ID NO:1 on the same epitope as the antibody produced by the hybridoma deposited in the ATCC under Accession No. PTA-7625 for a time sufficient for the first antibody or antigen-binding fragment thereof to bind to a neublastin polypeptide, if present in the sample;   contacting the sample with a second antibody or antigen-binding fragment thereof that selectively binds to the polypeptide of SEQ ID NO:1 on the same epitope as the antibody produced by the hybridoma deposited in the ATCC under Accession No. PTA 7625 for a time sufficient for the second antibody or antigen-binding fragment thereof to bind to the neublastin polypeptide, if bound to the first antibody or antigen-binding fragment thereof; and   detecting the presence or amount of the second antibody or antigen-binding fragment thereof bound to the neublastin polypeptide, to thereby determine the presence or amount of the neublastin polypeptide in the sample.   
     
     
         19 . The method of  claim 18 , wherein the first antibody is produced by the hybridoma deposited in the ATCC under Accession No. PTA-7625. 
     
     
         20 . The method of  claim 18 , wherein the second antibody is produced by the hybridoma deposited in the ATCC under Accession No. PTA-7625. 
     
     
         21 . The method of  claim 13 , wherein the method is a sandwich-based immunoassay. 
     
     
         22 . The method of  claim 13 , wherein the sample is obtained from a mammal. 
     
     
         23 . The method of  claim 22 , wherein the neublastin polypeptide is endogenous, wild-type neublastin. 
     
     
         24 . The method of  claim 13 , wherein the neublastin polypeptide comprises an amino acid sequence that is at least 80% identical to amino acids 15-113 of SEQ ID NO:1 and the polypeptide, when dimerized, binds to a complex containing GFRalpha3 and RET, and wherein the sample is obtained from a mammal to which the neublastin polypeptide has been administered. 
     
     
         25 . The method of  claim 24 , wherein the amino acid sequence is at least 90% identical to amino acids 15-113 of SEQ ID NO:1. 
     
     
         26 . The method of  claim 24 , wherein the amino acid sequence is at least 95% identical to amino acids 15-113 of SEQ ID NO:1. 
     
     
         27 . The method of  claim 24 , wherein the amino acid sequence is at least 98% identical to amino acids 15-113 of SEQ ID NO:1. 
     
     
         28 . The method of  claim 24 , wherein the polypeptide comprises amino acids 15-113 of SEQ ID NO:1, amino acids 15-113 of SEQ ID NO:2, amino acids 15-113 of SEQ ID NO:3, amino acids 15-113 of SEQ ID NO:4, amino acids 15-113 of SEQ ID NO:5, amino acids 15-113 of SEQ ID NO:8, or amino acids 15-113 of SEQ ID NO:9. 
     
     
         29 . The method of  claim 24 , wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:1, the amino acid sequence of SEQ ID NO:2, the amino acid sequence of SEQ ID NO:3, the amino acid sequence of SEQ ID NO:4, the amino acid sequence of SEQ ID NO:5, the amino acid sequence of SEQ ID NO:8, or the amino acid sequence of SEQ ID NO:9. 
     
     
         30 . The method of  claim 24 , wherein the polypeptide comprises amino acids 10-113 of SEQ ID NO:1. 
     
     
         31 . The method of  claim 13 , wherein the sample is blood, serum, saliva, semen, urine, lacrimal fluid, or cerebral spinal fluid. 
     
     
         32 . A method of antagonizing neublastin activity, the method comprising administering to a mammal an amount of the antibody or antigen-binding fragment thereof of  claim 1  effective to reduce or eliminate the ability of endogenous, wild-type neublastin to bind to a complex comprising RET and GFRalpha3 and induce dimerization and autophosphorylation of RET. 
     
     
         33 . A method of treating a cancer, the method comprising administering to a mammal having a cancer a pharmaceutical composition comprising a therapeutically effective amount of the antibody or antigen-binding fragment thereof of  claim 1 . 
     
     
         34 . The method of  claim 33 , wherein the cancer is a pancreatic cancer. 
     
     
         35 . The method of  claim 22 , wherein the mammal is a human.

Join the waitlist — get patent alerts

Track US2011135648A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.